ADXN vs MMTZF
Addex Therapeutics Ltd. and MindMaze Therapeutics Holding SA, side by side — 3 fiscal years reported in CHF, drawn from SEC filings.
Most recent reported year
| Metric | ADXN | MMTZF |
|---|---|---|
| Revenue | CHF 404,102 | CHF 6.3M |
| Net income | CHF 7.1M | CHF -98.2M |
| Gross margin | · | · |
| Net margin | · | · |
| Return on equity | 130.4% | −99.4% |
| Diluted EPS | CHF 0.07 | −CHF 8.35 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | CHF -5.4M | CHF -18.1M |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 4.42× | 2.65× |
| Revenue CAGR 5y | −31.9% | · |
| Profit CAGR 5y | · | · |
MMTZF bills 15.7× the revenue of ADXN, and MMTZF closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | ADXN | MMTZF |
|---|---|---|
| FY2023 | CHF 1.6M | CHF 6.3M |
| FY2022 | CHF 1.4M | CHF 7.1M |
| FY2021 | CHF 2.9M | CHF 4.5M |
Bottom line
| Fiscal year | ADXN | MMTZF |
|---|---|---|
| FY2023 | CHF -10.6M | CHF -98.2M |
| FY2022 | CHF -20.8M | CHF -50.8M |
| FY2021 | CHF -15.4M | CHF -34.7M |
Standard deviation, each side
ADXN's return on equity has been more volatile than MMTZF's over the 3 comparable fiscal years — 103.7 percentage points of standard deviation against 35.3.
3 of 8 comparable fiscal years — a year missing data on either side is not counted.
Year by year
MMTZF led in return on equity in every one of the 3 comparable fiscal years — a structural lead, not a recent swing.
3 of 8 comparable fiscal years — a year missing data on either side is not counted.